Keywords
- Cystic Fibrosis
- Gene Therapy
- Gene Delivery
- Cystic Fibrosis Transmembrane Conductance Regulator
- Atrial Natriuretic Peptide
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsBibliography
Alba R, Bosch A, Chillou M. 2005. Gutless adenovirus: Last generation adenovirus for gene therapy. Gene Ther. 12:518–527.
Alemany R. 2007. Cancer selective adenoviruses. Mol Aspects Med. 28:42–58.
Amalfitano A, Parks RJ. 2002. Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther. 2:111–133.
Anderson WF, Fletcher JC. 1980. Gene therapy in human beings: When is it ethical to bring? NEJM. 303:1293–1297.
Anderson WF. 1984. Prospects for human gene therapy. Science. 226:401–409.
Anderson WF. 1992. Human gene therapy. Science. 256:808–813.
Anson DS, Smith GJ, Parsons DW. 2006. Gene therapy for cystic fibrosis airway disease – Is clinical success imminent? Curr Gene Ther. 6:161–179.
Baum C, Dullmann J, Li Z, Fehse B, et al. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 101:2099–2114.
Blaese RM, Culver KW, Miller AD, Carter CS, et al. 1995. T lymphocyte directed gene therapy for ADA deficiency SCID: Initial trial results after four years. Science. 270:475–480.
Boucher RC. 1999. Status of gene therapy for cystic fibrosis lung disease. J Clin Inv. 103:441–445.
Brand TC, Tolcher AW. 2006. Management of high risk metastatic prostate cancer: The case for novel therapies. J Urol. 176:576–580.
Brunetti-Pierri N, Ng P. 2006. Progress towards the application of helper-dependent adenoviral vectors for liver and lung gene therapy. Curr Opin Mol Ther. 8:446–454.
Caplen NJ. 2003. RNA1 as a gene therapy approach. Expert Opin Biol Ther 3:575–586.
Cavazzana-Calvo M, Thrasher A, Mavilio F. 2004. The future of gene therapy. Nature. 427:779–781.
Cavazzana-Calvo M, Fischer A. 2007. Gene therapy for severe combined immunodeficiency: Are we there yet? J Clin Inv. 117:1456–1465.
Crittenden M, Gough M, Chester J, Kottle T, et al. 2003. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res. 63:3173–3180.
Culver KW. 1996. Gene Therapy. A Primer for Physicians, Mary Ann Liebert Inc., New York.
DiPaola RS, Plante M, Kaufman H, Petrylak DP, et al. 2006. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1 and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 4:1–1.
Djordjevic M. 2007. SELEX experiments: New prospects, applications and data analysis in inferring regulatory pathways. Biomol Eng. 24:179–189.
Dodge JA. 1998. Gene therapy for cystic fibrosis: What message for the recipient? Thorax. 53:157–158.
Eck SL, Wilson JM. 1996. Gene-based therapy. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE, et al., Eds. McGraw Hill, New York, pp. 77–1022.
Editorial, 1997. Supervising gene therapy openly. Lancet. 350:79.
Einfeld DA, Roelvink PW. 2002. Advances towards targetable adenovirus targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther. 4:444–451.
Epstein AL, Marconi P, Argnani R, Manservigi R. 2005. HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther. 5:445–448.
Flotte TR, Carter BJ. 1997. In vivo gene therapy associated with adeno-associated virus vectors for cystic fibrosis. Adv. Pharmacol. 40:85–101.
Freidmann T. 1989. Progress toward human gene therapy. Science. 244:1275–1281.
Fuch M. 2006. Gene therapy: An ethical profile of a new medical territory. J Gene Med. 8:1358–1362.
Galanis E, Vile R, Russell SJ. 2001. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 38:177–192.
Galanis E, Okuno SH, Nascimento AG, Lewis BD, et al. 2005. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12:437–445.
Gardlik R, Palffy R, Hodosy J, Lukacs J, et al. 2005. Vectors and delivery systems in gene therapy. Med Sci Monitor. 11:RA110–121.
Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC, et al. 2006. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: Three year clinical experience. Int J Oncol. 29:1053–1064.
Gordon EM, Chan MT, Geraldino N, Lopez FF, et al. 2007. Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol. 30:1297–1307.
Gutermann A, Mayer E, von-Dehn-Rothfelser K, Breidenstein C, et al. 2006. Efficacy of oncolytic herpes virus NV1020 can be enhanced in combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther. 17:1241–1253.
Harris JD, Evans V, Owen JS. 2006. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther. 8:275–287.
Hege KM, Jooss K, Pardoll D. 2006. GM-CSF gene modified cancer cell immunotherapies: Of mice and men. Int Rev Immunol. 25:321–352.
Hermonat PL, Mehta JL. 2004. Potential of gene therapy for myocardial ischemia. Curr Opin Cariol. 19:517–523.
Joyner A, Keller G, Phillips RA, Bernstein A. 1983. Retrovirus transfer of a bacterial gene into mouse hematopoietic progenitor cells. Nature. 305:556–558.
Kaiser J. 2005. Gene therapy. Putting the fingers on gene repair. Science. 310:1894–1896.
Kanai R, Tomita H, Hirose Y, Ohba S, et al. 2007. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP345 under the transcriptional control of musashi 1 promoter in the treatment of malignant glioma. Hum Gene Ther. 18:63–73.
Kanerva A, Hemminki A. 2005. Adenoviruses for treatment of cancer. Ann Med. 37:33–43.
Kaplan JM. 2005. Adenovirus based cancer gene therapy. Curr Gene Ther. 5:595–605.
Katz B, Goldbaum M. 2006. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF). Int Opthamol Clin. 46:141–154.
Kaufman HL, Cohen S, Cheung K, DeRaffele G, et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 17:239–244.
Kay MA, Liu D, Hoogerbrugge G. 1997. Gene therapy. Proc Nat Acad Sci. USA. 94:12744–12746.
Kay MA, Glorioso JC, Naldini L. 2001. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med. 7:33–40.
Kemeny N, Brown K, Covey A, Kim T, et al. 2006. Phase I. Open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther. 17:1214–1224.
Kim HJ, Jang SY, Park JI, Byun J, eet al. 2004. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med. 36:336–344.
Kolb M, Martin G, Medina M, Ask K, et al. 2006. Gene therapy for pulmonary diseases. Chest. 130:879–884.
Kootstra NA, Verma IM. 2003. Gene therapy with viral vectors. Ann Rev Pharmacol Toxicol. 43:413–439.
Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, et al. 2007. Combination therapy of an orthotropic renal cell carcinoma model using intratumoral vector-mediated costimulation of systemic interleukin-2. Clin Canc Res. 13:1936–1946.
Kyte JA, Mu L, Aamadal S, Kvalheim G, et al. 2006. Phase I/II trial of melanoma therapy with dendritic cells transfected with tumor-RNA. Cancer Gene Ther. 13:905–918.
Levine BL, Humeau LM, Boyer J, Rebello T, et al. 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS. 103:17372–17377.
Levy B, Panicalli D, Marshall J. 2004. TRICOM: Enhanced vaccine as anticancer therapy. Exp Rev Vaccines. 3:397–402.
Li D, Jiang W, Bishop S, Ralston R, et al. 1999. Combination surgery and nonviral Interleukin-2 gene therapy for head and neck cancer. Clin Cancer Res. 5:1551–1556.
Li D, Shugert E, Guo M, Bishop JS, et al. 2001. Combination non viral interleukin-2 and interleukin-12 gene therapy for head and neck squamous cell carcinoma. 127:1319–1324.
Li M, Li H, Rossi JJ. 2006. RNAi in combination with ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann NY Acad Sci. 1082:172–179.
Li SD, Huang L. 2006. Gene therapy progress and prospects. Gene Ther. 13:1313–1319.
Liu L, Liu H, Visner G, Fletcher BS. 2006. Sleeping beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB J. 20:2594–2596.
Lou E, Marshall J, Aklilu M, Cole D, et al. 2006. A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastasis of colorectal carcinoma. Clin Colorectal Cancer 5:368–371.
Lu X, Yu Q, Binder GK, Chen Z, et al. 2004. Antisense-mediated inhibition of human immunodeficiency virus replication by use of an HIV type I based vector results in severely attenuated mutants incapable of developing resistance. J Virol. 78:7079–7088.
Lundstrom K, boulikas T. 2003. Viral and nonviral vectors in gene therapy: Technology development and clinical trials. Technol Canc Res Treat. 2:471–486.
Luque F, Oya R, Macias D, Saniger L. 2005. Gene therapy for HIV infection: Are lethal genes a valuable tool? Cell Mol Biol. 51:93–101.
Madan RA, Arlen PM, Gulley JL. 2007. PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 7:543–544.
Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell. 33:153–159.
Marathe JG, Wooley DP. 2007. Is gene therapy a good therapeutic approach for HIV positive patients? Genet Vaccines Ther 5:5–5.
McConnell MJ, Imperiale MJ. 2004. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther. 15:1022–1033.
McLaughlin JM, McCarty TM, Cunningham C, Clark V, et al. 2005. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long term followup. Ann Surg Oncol. 12:825–830.
Middleton PG, Alton EW. 1998. Gene therapy for cystic fibrosis: Which postman, which box? Thorax. 53:197–199.
Miller AD, Jolly DJ, Friedmann T, Verma IM. 1983. A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): Gene transfer into cells obtained from human deficient in HPRT. Proc Nat Acad Sci USA. 80:4709–4713.
Miller AD. 1992. Human gene therapy come of age. Nature. 357:455–460.
Neff T, Beard BC, Kiem HP. 2006. Survival of the fittest in vivo selection and stem cell gene therapy. Blood. 107:1751–1760.
Nemunaitis J. 2005. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Exp Rev Vaccines. 4:259–274.
Nemunaitis J, Murray N. 2006. Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol. 1:756–761.
Nemunaitis J, Nemunaitis J. 2007. A review of vaccine clinical trials for non-small cell lung cancer. Exp Opin Biol Ther. 7:89–102.
Niidome T, Huang L. 2002. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 9:1647–1652.
Noe F, Nissinen J, Pitkanen A, Gobbi M., et al. 2007. Gene therapy in epilepsy, the focus on HPY. Peptides. 28:377–383
Osterman JV, Waddell A, Aposhian HV. 1970. DNA and gene therapy: Uncoating of polyoma pseudovirus in mouse embryo cells. Proc Nat Acad Sci USA. 67:37–40.
Palmer DH, Young LS, Mautner V. 2006. Cancer gene therapy: Clinical trials. Trends Biotechnol. 24:76–82.
Petrulio CA, Kaufman HL. 2006. Development of the PANVAC-VF vaccine for pancreatic cancer. Exp Rev Vaccines 5:9–19.
Philpott NJ, Thrasher AJ. 2007. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther. 18:483–489.
Pickles RJ. 2004. Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium. Proc Am Thorac Soc. 1:302–308.
Ponnazhagam S, Curiel DT, Shaw DR, Alvarez RD, et al. 2001. Adeno-associated virus for cancer gene therapy. Canc Res. 61:6313–6321.
Poreteus MH, Connelly JP, Pruett SM. 2006. A look to future directions in gene therapy research. PLOS Genet. 2:133–2141.
Prchal JT. 2003. Delivery on demand – A new era of gene therapy? NEJM. 348:1282–1283.
Preuss MA, Curiel DT. 2007. Gene therapy: Science fiction or reality? South Med J. 100:101–104.
Puck JM, Malech HL. 2006. Gene therapy for immune disorders: Good news tampered by bad news. J All Clin Immunol. 117:865–869.
Puddu GM, Cravero E, Ferrari E, Muscari A, et al. 2007. Gene based therapy for hypertension – Do preclinical data suggest a promising future? Cardiology. 108:40–47.
Puhlmann M, Brown CK, Gnant M, Huang J, et al. 2000. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7:66–73.
Qian SH, Channon K, Neplioueva V, Wang Q, et al. 2001. Improved adenoviral vector for vascular gene therapy. Circ Res. 88:911–917.
Que NS, Sallenger BA. 2007. Gene therapy progress and prospects; RNA aptamers. Gene Ther. 14:283–291.
Que-Gewirth NS, Sullenger BA. 2007. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 14:283–291.
Rainov NG, Ren H. 2003. Clinical trials with retrovirus mediated gene therapy – What have we learned? J Neurooncol. 65:227–236.
Raizada MK, Der-Sarkissian S. 2006. Potential of gene therapy strategy for the treatment of hypertension. Hypertension. 47:6–9.
Ramqvist T, Andreasson K, Dalianis T. 2007. Vaccination, immune and gene therapy based on virus-like particles against viral infection and cancer. Exp Opin Biol Ther 7:997–1007.
Rein DT, Breidenbach M, Curiel DT. 2006. Current developments in adenovirus based cancer gene therapy. Future Oncol. 2:137–143.
Romano G. 2006. The controversial role of adenoviral-derived vectors in gene therapy programs: Where do we stand? Drug News Persp. 19:99–106.
Rosenecker J, Huth S, Rudolph C. 2006. Gene therapy for cystic fibrosis lung disease: Current status and future perspectives. Curr Opin Mol Ther. 8:439–445.
Sabbioni S, Callegari E, Manservigi M, Argnani R, et al. 2007. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA. Gene Ther. 14:459–464.
Salmons B, Gunzburg WH. 1993. Targeting of retroviral vectors for gene therapy. Hum Gene Ther. 4:129–141.
Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, et al. 2006. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Nat Acad Sci USA. 27:13789–13794.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, et al. 204. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol. 22:592–601.
Shen Y, Nemunaitis J. 2006. Herpes simplex virus 1 (SHV-1) for cancer treatment. Cancer Gene Ther. 13:975–992.
Shichiri M, Tanaka A, Hirata Y. 2003. Intravenous gene therapy for familial hypercholesterolemia using ligand facilitated transfer of liposomes LDL receptor gene complex. Gene Ther. 10:827–831.
Simon JW, Sacks N. 2006. Granulocyte-macrophage colony stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol Oncol. 24:419–424.
Small EJ, Sacks N, Neumanitis J, Urba WJ, et al. 2007. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 13:3883–3891.
Song S, Morgan M, Ellis T, Poirier A, et al. 1998. Sustained secretion of human-alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Nat Acad Sci. 95:14384–14388.
Tan PH, Tan PL, George AJ, Chan CL. 2006. Gene therapy for transplantation for viral vectors – How much of the promise has been realized? Expert Opin Biol Ther. 6:759–772.
Tatum EL. 1966. Molecular biology, nucleic acids and the future of medicine. Persp Biol Med. 10:19–32.
Thomson L. 1994. Correcting the Code: Inventing and Genetic Cure for Human Body. Simon and Schuster, New York. pp.189–267.
Tomanin R, Scarpa M. 2004. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther. 4:357–372.
Tsai TH, Chen SL, Xiao X, Chiang YH, et al. 2006. Gene therapy of focal cerebral ischemia using defective recombinant adeno-associated virus vectors. Front Biosci. 11:2061–2070.
Vahakangas E, Yla-Herttuala S. 2005. Gene therapy of atherosclerosis. Handbook Exp Pharm. 170:785–807.
Verma IM, Weitzman MD. 2005. Gene therapy twenty first century medicine. Ann Rev Biochem. 74:711–738.
Von-Laer D, Hasselmann S, Hasselmann K. 2006. Gene therapy for HIV infection: What does it need to make it work? J Gene Med 8:658–667.
Vorburger SA, Hunt KK. 2002. Adenoviral gene therapy. The Oncologist 7:46–59.
Watanabe S, Temin HM. 1983. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol. 3:2241–2249.
Weber E, Anderson WF, Kasahara N. 2001. Recent advances in retrovirus vector-mediated gene therapy: Teaching an old vector new tricks. Curr Opin Mol Ther. 3:439–453.
White AF, Ponnazhagan S. 2006. Airway epithelium directed gene therapy for cystic fibrosis. Med Chem. 2:499–503.
Wigler M, Silverstein S, Lee LS, Pellicer A, et al. 1977. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 11:223–232.
Wolff JA. 1994. Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Birkhauser, Boston, MA.
Wolff JA, Lederberg J. 1994. An early history of gene transfer and therapy. Hum Gene Ther. 5:469–480.
Woods NB, Ooka A, Karlsson S. 2002. Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia. 16:563–569.
Xiao W, Chirmule N, Berta SC, McCullough B, et al. 1999. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 73:3994–4003.
Young LS, Mautner V. 2001. The promise and potential hazards of adenovirus gene therapy. Gut. 48:733–736.
Young LS, Searle PF, Onion D, Mautner V. 2006. Viral gene therapy strategies. J Pathol. 208:299–318.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Khan, M.M. (2008). Gene Therapy. In: Immunopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77976-8_10
Download citation
DOI: https://doi.org/10.1007/978-0-387-77976-8_10
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-77975-1
Online ISBN: 978-0-387-77976-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)